Infectious Disease and Drug Discovery Meeting

Bentley University
Waltham, MA 
June 20, 2008


8:00 - 9:00 am Check-in and breakfast
9:00 - 9:05 am

Opening Remarks
Marc Jacobs, Vertex Pharmaceuticals

9:05 - 10:00 am Antibacterial Drug Discovery in the 21st Century: Is There Any Hope?
Steve Projan, Wyeth Research, Cambridge, MA
10:00 - 10:30 am Riboswitches: RNA receptors as antibacterial drug targets
Ken Blount, Biorelix Pharmaceutical, Inc, New Haven, CT
10:30 - 11:00 am Break
11:00 - 11:30 am Structure Guided Target Evaluation for Antibacterial Drug Discovery
Sushmita Lahiri, AstraZeneca Pharmaceuticals, Waltham, MA
11:30 - 12:00 pm Structure-based Drug Design Targeting Infectious Disease
Zoltan Kanyo, Rib-X Pharmaceuticals, New Haven, CT
12:00 - 1:00 pm Lunch
1:00 - 2:00 pm Structural Biology and an Effective HIV-1 Vaccine
Peter Kwong, Vaccine Research Center, NIH, Bethesda, MD
2:00 - 3:00 pm Reducing Risk in Drug Discovery, Preclinical Development of the Hepatitis C Virus
Protease Inhibitor Telaprevir (VX-950)

Ann Kwong, Vertex Pharmaceuticals, Cambridge, MA
3:00 - 3:30 pm Break
3:30 - 4:00 pm Biophysical Approaches to Target-Based Discovery of Novel Antibacterials
Gunther Kern, AstraZeneca Pharmaceuticals, Waltham, MA
4:00 - 5:00 pm Mining the Magic Mountain for Novel Inhibitors of Menaquinone and Fatty Acid Biosynthesis
in Mycobacterium Tuberculosis: Slow Onset Inhibition and In Vivo Activity

Peter Tonge, Institute for Chemical Biology and Drug Discovery,
SUNY Stony Brook, NY
5:00 - 7:00 pm Mixer

Back to top